Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer

The vast majority of studies investigating immune checkpoint inhibition (ICI) in patients with breast cancer have focused on triple-negative breast cancer (TNBC). In this study, we compared the tumor immune microenvironment (TIME) between TNBC and hormone receptor-negative HER2-positive breast cance...

Descripción completa

Detalles Bibliográficos
Autores principales: Vos, Hanne, Lambein, Kathleen, Richard, François, Mariën, Bram, Nevelsteen, Ines, Punie, Kevin, Wildiers, Hans, Berben, Lieze, Laenen, Annouschka, Floris, Giuseppe, Desmedt, Christine, Smeets, Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460670/
https://www.ncbi.nlm.nih.gov/pubmed/34556657
http://dx.doi.org/10.1038/s41523-021-00332-7
Descripción
Sumario:The vast majority of studies investigating immune checkpoint inhibition (ICI) in patients with breast cancer have focused on triple-negative breast cancer (TNBC). In this study, we compared the tumor immune microenvironment (TIME) between TNBC and hormone receptor-negative HER2-positive breast cancer based on a selection of immune markers at the protein level in an institutional retrospective series. Additionally, we performed a similar comparison using publicly available transcriptomics data. Altogether, the results show a comparable TIME in both groups, with possible implications for the use of ICI in patients with hormone receptor-negative HER2-positive breast tumors.

Ejemplares similares